Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: fairly quiet, some bounces after Friday’s decline

July 6, 2021 7:47am

Pre-open indications: 6 BUYs: AGTC, BLUE, CLLS, IONS, NTLA, SGMO; 4 Sells: PGRN, CRSP, EDIT, VYGR; 1 Maintain SELL: BSTG

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming in July, it’s not conscription but, an offer to join our collective of like-minded investors!

Dow futures are DOWN -0.07% (-25 points), S&P futures are DOWN -0.02% (-1 point) and NASDAQ futures are UP +0.18% (+27 points)

Pre-mark futures were flat on Tuesday as the stock markets gets set to kick off the holiday-shortened week,

European stocks were muted after oil market talks were abandoned,

Asia-Pacific markets struggled for direction as investors reacted to the Australian central bank’s interest rate decision.

Henry’omics:

Yesterday with our market’s closed, European stocks closed higher; Asia-Pacific stocks were mixed on Monday while we were closed for a holiday

The S&P 500 is coming off a seven-day winning streak, its longest since August, amid a string of solid economic reports including a better-than-expected jobs report on Friday and the Nasdaq also reached a record high in the previous session.

Friday’s evening’s recap: “the cell and gene therapy sector collapsed after a sloppy week” … https://www.regmedinvestors.com/articles/11984

The Nasdaq closed UP +116.95 points (+0.81%);
The IBB closed down -0.22% and XBI closed down -2.42%;
Sector volume was LOW with 1 of the 9-upside having higher than the 3-month average volume with LOW volume of 4 of 24-downside having higher than the 3-month average volume;
The CBOE Volatility Index (VVIX: INDEX) was down -0.41 points or -2.65% at 15.07;
Friday’s percentage (%) of the 9-upside were +0.11% (RARE) to +2.49% (AGTC) while the 24-downside ranges from -0.21% (KDNY) to -7.90% (GBT);

Q3/21: 1 positive and 1 negative close

Q2/21:

June: 15 positive and 8 negative closes
May: 8 positive, 12 negative closes and 1 holiday
April: 11 negative and 10 positive closes

Q1/21:

March: 10 positive, 12 negative and 1 neutral closes
February: 9 positive, 10 negative closes and 1 holiday
January: 10 positive, 9 negative closes and 1 holiday

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) - Maintaining Sell – Could the share price stay up if it wasn’t “pumped”?

Biostage (BSTG) closed down -$0.00 with 1,974 shares traded after Thursday’s +$0.095 to $1.35 with 408 shares traded following Wednesday’s -$0.005 to $1.25 with 3,241 shares traded, Tuesday’s +$0.03 to $1.26 with 1,860 shares traded, Monday’s -$0.02 to $1.23 with 1,177 shares traded and last Friday’s -$0.10 to $1.25 with 1,00 shares traded.

Question#1: WHAT role is DST Capital “playing” in these on-going “volume-pumping” pricing “moves” – to keep the company from being de-listed?

Question#2: Does anyone see the patterns that I see?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

The morning’s indications:

SELL:

Precigen (PGEN) closed down -$0.13 to $6.42 and has a negative -$0.12 or -1.87% pre-market indication,

CRISPR Therapeutics (CRSP) closed down -$0.76 to $165.88 after Thursday’s -$5.25 to $156.64, Wednesday’s +$11.40 to $161.89 and last Tuesday’s -$1.14 to $150.49, with a negative -$3.70 or -2.37% pre-market indication.

Editas Medicine (EDIT) closed down again -$1.62 to $54.90 after Thursday’s -$0.12 to $56.52, Wednesday’s +$10.54 to $56.64 after last Tuesday’s +$2.11 to $46.10, and has a negative -$1.01 or -1.84% pre-market indication.

Voyager therapeutics (VYGR) +$0.04 to $4.12 with a negative -$0.14 or -3.40% pre-market indication.

BUY:

Applied Genetic Technologies (AGTC) closed up +$0.10 to $4.12 and has a positive +$0.02 or +0.49% pre-market indication;

bluebird bio (BLUE) closed down -$1.05 o to $31.37 with a positive +$1.02 or +3.25% pre-market indication.

Cellectis SA (CLLS) closed down -$0.93 to $15.16 with a positive +$0.11 or +0.73% pre-market indication,

Ionis Pharmaceuticals (IONS) closed down -$0.13 to $39.92 with a positive +$0.08 or +0.20% pre-market indication.

Intellia Therapeutics (NTLA) closed down -$7.94 to $163.71 after Thursday’s +$9.74 to $171.65, Wednesday’s +$10.30 to $161.91 and last Tuesday’s +$18.18 to $151.61, with a positive +$1.27 or +0.79% pre-market indication after closing a $600 M offering at $145.00.

Sangamo Therapeutics (SGMO) closed down -$0.30 to $11.71 with a positive +$0.23 or +1.96% pre-market indication

The BOTTOM LINE: In my role as a research analyst and journalist is a balancing “act”, WHAT CHANGES; many times, I scratch my head over how to cover volatile cell and gene therapy equities – it’s the INDICATIONS that focus my “leanings”.

I also continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped, fundamentals are being ignored.

There were three (3) negatives <Friday, Wednesday, Tuesday> closes and two (2) positives <Thursday, Monday> closes

After getting off Friday’s roller coaster, the only thing that could be a possibility is that a few of the downtrodden share pricings will be “recognized” and bounce upward.

My focus has always been “indication and warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.